drugset
drugset / Trial / NCT02171455

Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy Subjects

NCT02171455 ↗

Phase 1 Completed 10 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess safety, pharmacokinetics and the effect of dabigatran on coagulation parameters prior to administration of a high dose of dabigatran etexilate in a QT study

Timeline

Start
2006-01
Primary completion
2006-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 600 mg Oral
Subject Dabigatran etexilate Unknown 750 mg Oral
Subject Dabigatran etexilate Unknown 900 mg Oral

Indications

No indication recorded.